Lykos Therapeutics, the manufacturer of midomafetamine (MDMA), which had been tested for PTSD treatment, will reduce its workforce by 75% after the FDA rejected the company's new drug application.
The remaining workforce, led by senior medical adviser David Hough, MD, will focus on clinical development and FDA engagement, according to an Aug. 15 news release from Lykos.
Dr. Hough previously served as vice president of research and development at Johnson & Johnson Innovative Medicine.
As part of the reorganization, Rick Doblin, PhD, will step down from Lykos' board of directors. Dr. Doblin is the founder and president of the nonprofit behind Lykos, Multidisciplinary Association for Psychedelic Studies.